Bristol Myers Squibb (NYSE:BMY) Stock Price Target Lowered at Morgan Stanley

Bristol Myers Squibb (NYSE:BMY) had its price target cut by analysts at Morgan Stanley from $41.00 to $40.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “underweight” rating on the biopharmaceutical company’s stock. Morgan Stanley‘s price target suggests a potential downside of 36.43% from the stock’s previous close.

A number of other equities analysts have also weighed in on the company. Daiwa Securities Group lifted their price objective on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. Citigroup reiterated a “neutral” rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $65.46.

Bristol Myers Squibb Trading Up 2.5%

BMY traded up $1.54 during trading hours on Friday, reaching $62.93. 5,376,064 shares of the company’s stock traded hands, compared to its average volume of 12,008,648. The firm has a 50-day moving average price of $62.86 and a 200 day moving average price of $59.90. The firm has a market capitalization of $128.54 billion, a PE ratio of 13.86, a PEG ratio of 0.31 and a beta of 0.19. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a 52-week low of $45.20 and a 52-week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. The firm had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. Bristol Myers Squibb’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.63 earnings per share. As a group, sell-side analysts predict that Bristol Myers Squibb will post 6.46 EPS for the current fiscal year.

Insider Transactions at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC boosted its holdings in Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after acquiring an additional 368,193 shares during the period. Callan Family Office LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at $3,575,000. BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the period. Envestnet Asset Management Inc. lifted its holdings in Bristol Myers Squibb by 17.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock worth $123,465,000 after buying an additional 317,360 shares in the last quarter. Finally, Saudi Central Bank boosted its position in Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after buying an additional 67,780 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Third-quarter adjusted earnings of $1.35 per share exceeded the $1.10 consensus estimate, while revenue rose 6.9% year over year to $13.07 billion, beating expectations of $12.72 billion. Bristol-Myers Squibb Q3 earnings flash
• Positive Sentiment: Management raised its 2026 revenue outlook to approximately $50 billion, supported by strong demand for newer medicines. The Growth Portfolio grew 12% to $7.7 billion and supplied most of the quarterly revenue increase, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Continued Eliquis demand, progress across the development pipeline and reported cancer-trial advances strengthen the case that newer products can replace lost revenue over time. Barclays also maintained its Buy rating. Barclays maintains Buy rating
• Neutral Sentiment: Management highlighted artificial intelligence as a tool that is already accelerating drug research, but the financial impact remains difficult to quantify and is a longer-term consideration for investors. Bristol Myers discusses AI in drug research
• Negative Sentiment: Bristol Myers reduced its 2026 earnings outlook because higher in-process research and development charges are expected to weigh on profitability. Adjusted EPS also declined from $1.63 a year earlier to $1.35. Bristol Myers cuts EPS outlook
• Negative Sentiment: Opdivo sales came in below expectations, while patent expirations, launch execution and the challenge of replacing revenue from mature drugs remain important risks. Bristol Myers Opdivo sales and guidance

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.